The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
March 16, 2021
In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)
March 16, 2021 (Issue: 1619)
The FDA has approved a fixed-dose combination of
pertuzumab, trastuzumab, and hyaluronidase (Phesgo – Genentech) for use in combination with chemotherapy
for neoadjuvant (preoperative) treatment of human
epidermal growth factor receptor 2...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.